Clinical Trial Search

Primary: Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention) — 46.55; 47.63; 47.12; 47.03 units on…

Primary: Participants no Longer Meeting Criteria for Severe Aplastic Anemia. — 18; 17; 9; 9 participants

Primary: Core Body Temperature — 2.04; -0.05 Percent Change — p=0.0001

Primary: Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site Reactions — 558…

Primary: Percentage of Patients That Self-reported as Satisfied With Care for Depressive Symptoms. — 54.2; 18.8 percentage of participants

Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Phase I — 0; 1; 0; 0 participants

Primary: Response Rate at 6 Months — 1; 0; 0 participants

Primary: Number of Participants Completing Study Intervention — 7; 10; 3; 5 Participants

Primary: Total Symptoms Score — 2.5; 3.1 units on a scale — p=< 0.05

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: Safety — 10 participants

Primary: Mean Asymmetry of the Patella After Patella Resection — 1.73; 1.40; 0.85 mm — p=0.001

Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…

Primary: Presence of Scarring — 1; 1 participants

Primary: Biologic Effects by Coagulation Tests — 34.75; 143.4 percentage of normal